[Lotus] Subsidiary Alvogen Korea Acquires Marketing Authorization for Product 'Matterhorn' in the Korean Market from OM PHARMA SA
Lotus Pharmaceutical (Taiwan) announced that its subsidiary, Alvogen Korea, has decided to acquire intellectual property rights, marketing authorizations, and product technology related to 'Matterhorn' for the Korean market from OM PHARMA SA for 69 million USD.
📋 Article Processing Timeline
- 📰 Published: May 21, 2026 at 09:00
- 🔍 Collected: May 22, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 22, 2026 at 08:03 (3 min after Collected)
1. Name and Nature of Target Object: Intellectual property rights, marketing authorizations, and product technology for the product 'Matterhorn' sold in the Korean market by OM PHARMA SA.
2. Date of Occurrence: May 21, 2026.
3. Board Approval Date: May 21, 2026.
5. Transaction Quantity, Unit Price, and Total Amount: 69 million USD.
6. Counterparty: OM PHARMA SA (Not a related party).
11. Payment Terms: Based on contractual conditions.
12. Basis for Decision: Approved by the Board of Directors after considering the valuation report provided by an independent expert.
17. Objective of Acquisition: Optimization of product portfolio.
20. Audit Committee Approval Date: May 20, 2026.
28. Source of Funding: Own funds and bank loans.
30. Other: The transaction amount is calculated based on the Taiwan Bank exchange rate on May 19, 2026, at 1 USD to 31.65 TWD.
2. Date of Occurrence: May 21, 2026.
3. Board Approval Date: May 21, 2026.
5. Transaction Quantity, Unit Price, and Total Amount: 69 million USD.
6. Counterparty: OM PHARMA SA (Not a related party).
11. Payment Terms: Based on contractual conditions.
12. Basis for Decision: Approved by the Board of Directors after considering the valuation report provided by an independent expert.
17. Objective of Acquisition: Optimization of product portfolio.
20. Audit Committee Approval Date: May 20, 2026.
28. Source of Funding: Own funds and bank loans.
30. Other: The transaction amount is calculated based on the Taiwan Bank exchange rate on May 19, 2026, at 1 USD to 31.65 TWD.
FAQ
What product did Alvogen Korea acquire marketing rights for from OM PHARMA SA in 2024?
Alvogen Korea acquired marketing rights for the product 'Matterhorn' from OM PHARMA SA in 2024.
How much did Alvogen Korea pay to OM PHARMA SA for the Matterhorn acquisition in 2024?
Alvogen Korea paid 69 million USD to OM PHARMA SA for the Matterhorn acquisition in 2024.
Which company is the parent of Alvogen Korea that announced the Matterhorn deal in 2024?
Lotus Pharmaceutical (Taiwan) is the parent company of Alvogen Korea that announced the Matterhorn deal in 2024.
What specific rights did Alvogen Korea acquire for Matterhorn from OM PHARMA SA in 2024?
Alvogen Korea acquired intellectual property rights, marketing authorizations, and product technology for Matterhorn in 2024.
In which market will Alvogen Korea commercialize Matterhorn after the 2024 acquisition from OM PHARMA SA?
Alvogen Korea will commercialize Matterhorn in the Korean market after the 2024 acquisition from OM PHARMA SA.